Axial Biotech

Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients. Satiety's first product, the TOGA System, enables physicians to perform a procedure similar to traditional restrictive obesity surgeries, but without surgical incisions. In this procedure, the TOGA System devices are inserted transorally (through the mouth) and are used to reduce the capacity of the stomach to give patients a feeling of fullness after a small meal. The procedure is intended to be safer and easier for patients to tolerate than conventional obesity surgery. Safety and effectiveness of the TOGA System are currently being evaluated in a multi-center U.S. Study and the system is not available for sale in the United States.

NFlex is an engineered rod and spacer system that has been designed to precisely control the motion of unstable vertebral segments of the lumbar spine. The system aims to allow controlled spinal motion in flexion, extension and lateral bending, while limiting axial rotation and shear to very small amounts, these characteristics are similar to healthy lumbar spine motion. No other device on the market or in clinical trials can make the same claim.

Axis Surgical Technologies, Inc. aims to develop, manufacture, and market devices that improve quality and efficiency in spinal surgery, especially for minimally invasive surgical techniques. Based in Mountain View, California, Axis offers an integration of visualization and articulation capabilities and provides spinal surgery equipment. Axis' FDA Grant In March 2010, Axis announced that it received 510(k) clearance from the Food and Drug Administration to market its C-MOR„ Visualization Device to use in diagnostic and operative arthroscopic and endoscopic procedures. This portable tool provides visualization and illumination of an interior cavity through either a natural or surgical opening. The ergonomic lightweight device also offers practitioners the convenience of endoscopic visualization and efficient one-handed operating ability; this device can be employed in hospital outpatient departments, ambulatory surgery centers, and office surgery suites.

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

Spineology provides anatomy-conserving spinal technologies for surgeons and their patients. Spineology surgical techniques conserve spinal bone, ligament, and muscle tissue. Spineology is committed to increasing procedural efficiency, reducing surgical morbidity, and accelerating patient recovery.

MuscleMorph's technology is centered around a motion actuator that matches the performance of biological muscles enabling new medical device and robotic applications and potentially many others previously thought impossible. Penn graduates Rodrigo Alvarez and Rahul Kothari continue to be dedicated to the company's mission to revolutionize motion technology.